"The complexity of the FDA regulatory pathway and that of...

"The complexity of the FDA regulatory pathway and that of ourdevice/drug combination product necessitates that the Company has local experts to support both the clinicaland regulatory effort required to secure appropriate approvals for our precision surgery and digital pathologysolutions."

Almost there....almost. Alas, the burning question remains - what are the outstanding steps on the clinical and regulatory front for Invivage, taking into account recent advice from FDA?

Just based on the sentiment in the quote, I could hazard a guess at an answer to the above - but instead of guessing, it would be nice if the company could at least describe some of the basic forward clinical and regulatory milestones - instead of requiring us to make inferences based on sentiment at the very bottom of an announcement.

The communication style here, while vastly improved in recent years, still feel like a bit like small time company stuff. Better to rip the band-aid off if there is one to be ripped, with some straightforward and clear comms on remaining steps, or at the very least highlighting the points discussed with FDA in broad strokes? Or at the very very least, reflecting that feedback was officially received and that the company will be planning next steps - and will update us in due course?

Food for thought.